Jennifer Hudson, Earth, Wind & Fire and Jermaine Paul will perform at a tribute concert Oct. 27 celebrating Clive J. Davis at the 15th anniversary of the Multiple Myeloma Research Foundation Fall Gala in Greenwich.

The MMRF will honor Davis, a five-time Grammy Award winner and noted music industry executive, with the MMRF Spirit of Hope Award, presented annually to individuals who inspire hope with their perseverance in overcoming personal obstacles. Funds raised will support the development of life-extending treatments for multiple myeloma, an incurable blood cancer.

An Academy Award-winning actress, Grammy Award-winning recording artist, best-selling author and clothing designer, Hudson gained national acclaim in 2004 as a contestant on the third season of "American Idol." She made her award-winning film debut in the 2006 production of "Dreamgirls," and her chart-topping music debut in 2008 with Arista Records, which was founded by Davis. Hudson became the national spokesperson for Weight Watchers in 2010.

Earth, Wind & Fire was signed to Columbia Records in 1972 by Davis. With a career spanning more than four decades, six Grammy Awards, eight No. 1 R&B singles, eight Double Platinum Top 10 pop albums, and more than 90 million albums sold, VH1 ranked Earth, Wind & Fire as No. 60 on its list of the 100 Greatest Artists of Rock & Roll.

Winner of the second season of NBC's "The Voice," Paul is recording his debut album, which is set for release at the beginning of December. Paul previously sang background vocals for Alicia Keys, and performed on Keys' Grammy Award-winning album "The Diary of Alicia Keys," which was released by Davis' J Records, and was nominated for a Grammy for a duet on the album.

"I am proud to participate in this tribute concert for Clive Davis to benefit the MMRF -- an organization that has helped so many patients and families affected by this devastating cancer," Hudson said. "I hope my involvement will help the MMRF in their role of bringing new treatments and hope to cancer patients worldwide."

More Information

Fact box

The MMRF has been recognized as a ground-breaking cancer research organization. Significant MMRF achievements made possible by funding from programs like the Fall Gala include: opening more than 40 clinical trials with 21 novel treatments; sequencing the multiple myeloma genome; and helping to bring five new myeloma drugs to market in less than 10 years -- including the July 2012 FDA approval of Onyx Pharmaceuticals Inc.'s Kyprolis, to which the MMRF provided pivotal support to advance its development. Dr. N. Anthony Coles, president and CEO of Onyx Pharmaceuticals will receive the MMRF Corporate Leadership Award at the gala.

Despite the advancements made by the MMRF, the five-year survival rate for myeloma remains one of the lowest of all cancers and multiple myeloma remains incurable. In 2012, more than 20,000 adults in the United States will be diagnosed with multiple myeloma it is predicted that nearly 11,000 people will die from the disease. The funds raised by the MMRF are critical in continuing to advance research and the progress being made.

"We are so thankful to have Jennifer Hudson, Earth, Wind & Fire and Jermaine Paul joining the MMRF to help honor Clive Davis and support our urgent work," said New Canaan resident Kathy

Giusti, founder and CEO of the MMRF and a myeloma patient.

"The endorsement of our mission by these talented musicians, who are joining us to celebrate this momentous event, is critical to raising awareness for this rare cancer."

The annual gala has been attended by more than 1,200 people, including many celebrities, prominent business executives and high-impact philanthropists. To reserve a table for the MMRF Fall Gala, donate an auction item or inquire about sponsorship opportunities, email or call 888-584-5463.

MMRF was established in 1998 as a 501(c)(3) nonprofit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Giusti's diagnosis with multiple myeloma.

Its mission is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure.

As the world's No. 1 private funder of multiple myeloma research, the MMRF has raised more than $200 million since its inception and directs 90 percent of its total budget to research and related programming.

As a result, the MMRF has been awarded Charity Navigator's coveted four-star rating for nine consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency.

For more information about the MMRF, visit